Urs J. Hancox
Publications by Year
Research Areas
PI3K/AKT/mTOR signaling in cancer, Advanced Breast Cancer Therapies, Cancer Genomics and Diagnostics, Lung Cancer Treatments and Mutations, Cancer Treatment and Pharmacology
Most-Cited Works
- → Feedback Suppression of PI3Kα Signaling in PTEN-Mutated Tumors Is Relieved by Selective Inhibition of PI3Kβ(2014)261 cited
- → Inhibition of PI3Kβ Signaling with AZD8186 Inhibits Growth of PTEN-Deficient Breast and Prostate Tumors Alone and in Combination with Docetaxel(2014)99 cited
- → Discovery of (R)-8-(1-(3,5-Difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): A Potent and Selective Inhibitor of PI3Kβ and PI3Kδ for the Treatment of PTEN-Deficient Cancers(2014)86 cited
- → Small-molecule androgen receptor downregulators as an approach to treatment of advanced prostate cancer(2011)45 cited
- → Intermittent High-Dose Scheduling of AZD8835, a Novel Selective Inhibitor of PI3Kα and PI3Kδ, Demonstrates Treatment Strategies for PIK3CA -Dependent Breast Cancers(2016)42 cited
- → Discovery of 1-(4-(5-(5-amino-6-(5-tert-butyl-1,3,4-oxadiazol-2-yl)pyrazin-2-yl)-1-ethyl-1,2,4-triazol-3-yl)piperidin-1-yl)-3-hydroxypropan-1-one (AZD8835): A potent and selective inhibitor of PI3Kα and PI3Kδ for the treatment of cancers(2015)35 cited
- → Inhibiting PI3Kβ with AZD8186 Regulates Key Metabolic Pathways in PTEN-Null Tumors(2017)29 cited
- → Discovery of 9-(1-anilinoethyl)-2-morpholino-4-oxo-pyrido[1,2-a]pyrimidine-7-carboxamides as PI3Kβ/δ inhibitors for the treatment of PTEN-deficient tumours(2014)19 cited
- → The use of 18F-fluorodeoxyglucose positron emission tomography (18F-FDG PET) as a pathway-specific biomarker with AZD8186, a PI3Kβ/δ inhibitor(2016)18 cited
- → Synthesis and structure–activity relationships of thieno[2,3-b]pyrroles as antagonists of the GnRH receptor(2007)12 cited